UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 24.927

Sortiert nach

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Link zum Volltext

Verfügbarkeit prüfen

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

The lancet oncology, 2019-12, Vol.20 (12), p.1681-1690

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2016-11, Vol.34 (31), p.3740-3748

2016

Link zum Volltext

Verfügbarkeit prüfen

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1122-1128

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.74-89

2022

Link zum Volltext

Verfügbarkeit prüfen

Symptom experiences and health‐related quality of life among non‐small cell lung cancer patients participating in clinical trials

Journal of clinical nursing, 2019-06, Vol.28 (11-12), p.2111-2123

2019

Link zum Volltext

Verfügbarkeit prüfen

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Link zum Volltext

Verfügbarkeit prüfen

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Nature genetics, 2012-08, Vol.44 (8), p.852-860

2012

Link zum Volltext

Verfügbarkeit prüfen

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Oncoimmunology, 2018-01, Vol.7 (1), p.e1375642-e1375642

2018

Link zum Volltext

Verfügbarkeit prüfen

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.423-433

2022

Link zum Volltext

Verfügbarkeit prüfen

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Scientific reports, 2021-10, Vol.11 (1), p.19596-19596, Article 19596

2021

Link zum Volltext

Verfügbarkeit prüfen

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Critical reviews in oncology/hematology, 2022-12, Vol.180, p.103847-103847, Article 103847

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

PloS one, 2020-04, Vol.15 (4), p.e0231546-e0231546

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

PloS one, 2019-11, Vol.14 (11), p.e0224379-e0224379

2019

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

Cancer imaging, 2023-10, Vol.23 (1), p.1-102, Article 102

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

British journal of cancer, 2021-02, Vol.124 (4), p.713-720

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 24.927

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18.975)
Mit Volltextzugriff
(23.023)

Publikationsform

Artikel
(24.096)
Tagungsberichte
(705)
Buchkapitel
(104)
Bücher
(19)
Berichte
(3)

Sprache

Koreanisch
(23.309)
Englisch
(1.623)
Japanisch
(94)
Deutsch
(1)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.530)
농학
(1.131)
Humans
(908)
Technology
(833)
Engineering
(682)
Life Sciences & Biomedicine
(672)
Male
(668)
Materials Science
(668)
Materials Science, Multidisciplinary
(653)
Engineering, Multidisciplinary
(651)
Female
(631)
Middle Aged
(559)
Aged
(468)
Adult
(460)
내과학
(400)
생물학
(284)
약학
(231)
Helicobacter Pylori
(215)
Prognosis
(211)
Oncology
(184)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Symptom experiences and health‐related quality of life among non‐small cell lung cancer patients participating in clinical trials

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria

A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

Suchergebnisse filtern